Report Overview

Indian Huntingtons Disease Treatment Market size stood at USD XX Billion in 2019 and is projected to reach USD XX Billion by 2028, exhibiting a CAGR of XX% during the forecast period.

Huntingtons disease is one of the rare genetic condition that may affects the brain and can results in the degeneration of the nerve cells. It usually occurs between the ages of 30-50. The symptoms of the targeted disorder are depression, mood swings, amnesia, involuntary movement, and weight loss. It is associated with Parkinsons disease and Alzheimers as well as other health complications. Huntingtons disease can be diagnosed through CT scans and MRIs. In 2015, the prevalence of the disease in India is estimated to be approximately 3 to 5 per 1,00,000 people, which translates to about 40,000-70,000 individuals with HD.



Market Drivers

On-going scientific research responsible for awareness about Huntingtons disease amongst the population is considered as one of the major factors driving the growth of Huntingtons disease therapeutics market. Furthermore, high investment by the pharmaceutical companies involved in the R&D sector to develop innovative and curative drugs for the disease is fuelling the growth of the Indian HD treatment market. Besides, the presence of alternative therapies, including speech therapy, psychotherapy, and physiotherapy strongly contributed and increased the potential of the market growth for Huntingtons disease therapeutics.